First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.
- DOI
- 10.1093/oncolo/oyaf136
- Published
- 2025 Jul 4
- Container
- The oncologist
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/oncolo/oyaf136,
title = {First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.},
author = {Powderly JD 2nd and Gutierrez ME and Balmanoukian AS and Hoyle PE and Dong Z and Cheng L and Chen X and Janik JE and Bourayou N and Hamid O},
year = {2025},
journal = {The oncologist},
doi = {10.1093/oncolo/oyaf136},
url = {https://doi.org/10.1093/oncolo/oyaf136}
}RIS
TY - JOUR TI - First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors. AU - Powderly JD 2nd AU - Gutierrez ME AU - Balmanoukian AS AU - Hoyle PE AU - Dong Z AU - Cheng L AU - Chen X AU - Janik JE AU - Bourayou N AU - Hamid O PY - 2025 JO - The oncologist DO - 10.1093/oncolo/oyaf136 UR - https://doi.org/10.1093/oncolo/oyaf136 ER -
APA
2nd, P. J., ME, G., AS, B., PE, H., Z, D., L, C., X, C., JE, J., N, B., & O, H. (2025). First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.. The oncologist. https://doi.org/10.1093/oncolo/oyaf136
Source records
- pubmed · retrieved 2026-09-26T22:50:38.875Z
- europe-pmc · retrieved 2026-09-26T22:50:38.890Z